RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES

被引：0
|
作者：
Mufti, G. J. [1 ]
Estey, E. [2 ]
Popat, R. [3 ]
Mattison, R. [4 ]
Menne, T. [5 ]
Azar, J. [6 ]
Bloor, A. [7 ]
Gaymes, T. [1 ]
Khwaja, A. [3 ]
Juckett, M. [4 ]
Lennard, A. [5 ]
Zhang, C. [8 ]
Gallant, G. J. A. [8 ]
Gopal, A. K. [2 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[3] UCL, Inst Canc, London, England
[4] Univ Wisconsin, Madison, WI USA
[5] Newcastle Upon Tyne NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Christie Hosp NHS Trust, Manchester, Lancs, England
[8] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P180
引用
收藏
页码：33 / 34
页数：2
相关论文
共 50 条
  • [41] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K. Kumar
    James Jett
    Randolph Marks
    Ronald Richardson
    Fernando Quevedo
    Timothy Moynihan
    Gary Croghan
    Svetomir N. Markovic
    Keith C. Bible
    Rui Qin
    Angelina Tan
    Julian Molina
    Scott H. Kaufmann
    Charles Erlichman
    Alex A. Adjei
    Investigational New Drugs, 2013, 31 : 1201 - 1206
  • [42] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Kumar, Shaji K.
    Jett, James
    Marks, Randolph
    Richardson, Ronald
    Quevedo, Fernando
    Moynihan, Timothy
    Croghan, Gary
    Markovic, Svetomir N.
    Bible, Keith C.
    Qin, Rui
    Tan, Angelina
    Molina, Julian
    Kaufmann, Scott H.
    Erlichman, Charles
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1201 - 1206
  • [43] Deficiency of PARP-1 and PARP-2 in the mouse uterus results in decidualization failure and pregnancy loss
    Kelleher, Andrew M.
    Setlem, Rohit
    Dantzer, Francoise
    DeMayo, Francesco J.
    Lydon, John P.
    Kraus, W. Lee
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (40)
  • [44] Contribution of PARP-1 polymorphisms in nephropathy in type 2 diabetic patients
    Hadjadj, S.
    Piguel, X.
    Guilloteau, G.
    Dardari, D.
    Guerci, B.
    Matta, M.
    Halimi, J. -M.
    Verier-Mine, O.
    Roussel, R.
    Leroux, S.
    Bridoux, F.
    Marre, M.
    Marechaud, R.
    DIABETOLOGIA, 2008, 51 : S472 - S473
  • [45] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [46] A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
    Litton, Jennifer Keating
    Blum, Joanne Lorraine
    Im, Young-Hyuck
    Martin, Miguel
    Mina, Lida A.
    Roche, Henri Hubert
    Rugo, Hope S.
    Visco, Fran
    Zhang, Charlie
    Lokker, Nathalie Andrienne
    Lounsbury, Debra L.
    Eiermann, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] A phase 1 and pharmacodynamic study of PX-12, a thioredoxin inhibitor, in advanced malignancies
    Ramanathan, RK
    Dragovich, T
    Egorin, M
    Trump, D
    Sharlow, E
    Chow, S
    Kirkpatrick, DL
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S170 - S170
  • [48] Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
    Olmos, David
    Barker, Douglas
    Sharma, Rohini
    Brunetto, Andre T.
    Yap, Timothy A.
    Taegtmeyer, Anne B.
    Barriuso, Jorge
    Medani, Hanine
    Degenhardt, Yan Y.
    Allred, Alicia J.
    Smith, Deborah A.
    Murray, Sharon C.
    Lampkin, Thomas A.
    Dar, Mohammed M.
    Wilson, Richard
    de Bono, Johann S.
    Blagden, Sarah P.
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3420 - 3430
  • [49] Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results
    Smith, D. C.
    Infante, J. R.
    Siu, L. L.
    Sullivan, D.
    Vlahovic, G.
    Kauh, J.
    Blakemore, S. J.
    Gupta, N.
    Kalebic, T.
    Thompson, J. A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S147 - S147
  • [50] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
12345